(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

Varda Space Industries, Inc., a microgravity-enabled life sciences company, today announced the successful landing of its second reentry capsule, W-2, and the completion of the company's second ...

Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...

Dynaprice.com, Inc. today announced definitive agreement and completion of all closing conditions to merge with Dinamo Acquisition Corporation. Through this merger, control of the company passes to a ...

The Orphan Drugs Market is experiencing significant growth due to increasing investment in rare disease research, regulatory incentives, and advancements in biotechnology. Orphan drugs are specialized ...

Researchers conduct a retrospective, population-based cohort study of adult patients with metastatic breast cancer who underwent genomic profiling at academic institutions.

MacroGenics' valuation has declined due to continued bad news in 2024, impacting market sentiment. Click here to find out why ...

This partnership highlights both companies’ commitment to improving healthcare by equipping cardiologists with cutting-edge knowledge and skills in interventional cardiology. The MoU is part of a ...

Terumo Vietnam Medical Equipment (Terumo Vietnam) and Daiichi Sankyo Vietnam have signed a Memorandum of Understanding (MoU) ...

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...